What long-term health risks are known for Cosentyx (secukinumab)?
Cosentyx (secukinumab) is an IL‑17A inhibitor used for inflammatory conditions such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. Long-term risk concerns with this drug class center on infection risk and effects related to how IL‑17 supports immune defenses, especially against certain infections. Reported serious risks in prescribing information include serious infections and a higher chance of infections overall [1].
Other long-term considerations discussed for IL‑17 blockers include:
- Infections that may require medical attention, including serious or opportunistic infections in some cases [1]
- Potential worsening or emergence of inflammatory eye disease (uveitis has been reported with secukinumab and other IL‑17 inhibitors) [1]
- Gastrointestinal symptoms/IBD-related concerns have been a specific monitoring topic for IL‑17 inhibitors in clinical use, though exact long-term incidence varies by population and study design [1]
Do long-term studies show increased cancer risk?
Based on available published safety summaries and regulatory labeling, there is ongoing monitoring for malignancy risk with biologics like secukinumab, but no clear long-term cancer signal has been established in the labeling as a definitive, causal risk. The main labeled long-term safety emphasis remains infection and serious infection risk, with post-marketing surveillance continuing [1].
What infections should patients worry about long term?
Patients are generally advised to watch for infection symptoms (fever, persistent cough, burning with urination, skin infections, worsening fatigue) because IL‑17 inhibition can reduce immune responses to certain pathogens. The most important “long-term risk” is the possibility of serious infections occurring during treatment, which can require stopping the drug and urgent medical evaluation [1].
Does it raise risk for tuberculosis or other specific infections?
TB and other chronic infections are part of standard screening before starting biologics. In patients who have TB or are at risk, treatment can increase the chance of infection reactivation. Prescribing information for secukinumab includes screening and risk assessment expectations for tuberculosis and attention to infection history [1].
What happens to people with long-term use who develop new symptoms?
If symptoms develop that could reflect infection or inflammatory complications (for example, eye pain/redness with light sensitivity), patients should seek medical care promptly. This matters because some adverse effects are uncommon but clinically significant and may not be immediately obvious as “drug side effects” to patients [1].
Are there special long-term risks for older adults or people with other conditions?
People with conditions that increase infection risk (such as diabetes, chronic lung disease, frequent prior infections, or immunosuppressive therapies) may face higher practical risk when taking a biologic like Cosentyx. The labeled approach focuses on assessing infection risk, reviewing other medications that suppress immunity, and monitoring for infections over time [1].
How do patients typically reduce long-term risk?
The key practical steps are:
- Screening for TB and managing active infections before starting [1]
- Ongoing monitoring for infections while on therapy [1]
- Prompt evaluation of new symptoms (fever, signs of infection, and eye symptoms) rather than waiting for them to pass [1]
Sources
- Cosentyx (secukinumab) prescribing information (labeling). https://www.cosentyx.com/prescribing-information